We can show that treatment with NOX inhibitor blocks IFNγ production and diminishes Tc1 responses in Crohn's disease, perhaps indicating that inhibition of NOX2/ROS signalling could be further explored as a potential therapeutic target. Here, CYBB is linked to Crohn disease.